Oral administration of poly(ADP-ribose) polymerase inhibitor prevents intestinal damage induced by irinotecan and enhances the efficacy of irinotecan and temozolomide combination against colon carcinoma

Authors :: Zhang, J
Tentori, L
Leonetti, C
Scarsella, M
Muzi, A
Mazzon, E
Vergati, M
Forini, O
Lapidus, R
Xu, W
Cuzzocrea, S
Graziani, G
Publication Year :: 2006
Publisher :: America Associaton for Cancer Research, 2006.

Subjects :: coloncarcinoma
PARP inhibitor
DNA repair, chemoresistance, chemotoxicity, coloncarcinoma, combination therapy, temozolomide, irinotecan, PARP inhibitor
Settore BIO/14
DNA repair
chemoresistance
chemotoxicity
temozolomide
irinotecan
combination therapy

Tools